← Leaderboards
William Andrew Daunch
Focal Medical, Inc.
$6,184,629
Attributed
$6,184,629
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2017–22$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,184,629 · 1
By mechanism
R44$6,184,629 · 1
Top collaborators
No co-investigators on record.
Most similar at Focal Medical, Inc.
Same institution · by research overlap
- Stephanie Lemmo Ham$297,965
Others in their field
Other Emerging Leaders on “Implantable Device”
- Bryan L McLaughlin · Micro-Leads, Inc.$15,075,554
- Nanthia A Suthana · University Of California Los Angeles$12,232,599
- Shadi Dayeh · University Of California, San Diego$11,494,972
- Leah Johnson · Research Triangle Institute$10,876,154
- James N Campbell · Centrexion Therapeutics Corporation$8,662,635
- Chong Xie · University Of Texas At Austin$8,208,158
Research focus
Implantable DeviceImplantEnsureGemcitabineBiomaterial CompatibilityAnimal ModelDrug UsageEfficacy TestingCathetersDrug Delivery SystemsChemotherapeutic AgentChemotherapyBlood VesselsClinical TrialsAnimal TestingDrug TargetingEffectivenessDesignDevice DesignsDevice Or Instrument DevelopmentDevicesBaseDiagnosisImplantation
Grant awards (6)
Implantable iontophoresis chemotherapy delivery device for direct infusion ofgemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial$2,000,000
R44 · FY2022 · CA · contact PI
Implantable iontophoresis chemotherapy delivery device for direct infusion ofgemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial$2,000,000
R44 · FY2021 · CA · contact PI
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial$771,376
R44 · FY2019 · CA · contact PI
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial$2,084
R44 · FY2019 · CA · contact PI
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial$1,111,364
R44 · FY2018 · CA · contact PI
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial$299,805
R44 · FY2017 · CA · contact PI